Given the fact that natural IgM antibodies against oxLDL have been shown to ameliorate the adverse effects of oxLDL in several metabolic diseases, including NASH 17 and atherosclerosis 18, we assessed whether EO6 monoclonal antibodies against oxLDL were able to counteract the metabolic effects of oxLDL on HIF-1α and LC3B by treating KLM-1 cells for 8hr with oxLDL (50 μg/ml) in the presence or absence of EO6 (14 μg/ml). The gene discussed is MAP1LC3B; the disease is Other metabolic disease.